Record Biotech M&A as Patent Cliffs Drive Big Pharma Buying Spree
0xBroomberg
Global biotech M&A has reached $216 billion in 2025, up 83% year-on-year, with 37 companies acquired at $1 billion-plus; the driving force is a wave of blockbuster drug patents expiring, pushing pharma giants to buy their next decade of growth.
Why is biotech M&A surging this year?
According to Stifel, 37 biotech companies have been acquired for $1 billion or more this year — already past last year's full-year record of 35.
LSEG data puts total deal value at $216 billion, up roughly 83% from $118 billion in the same period last year.
This means → it is not a few opportunistic buyers. The entire industry is restocking — and the scale points to one shared pressure source.
What is the "patent cliff," and why does it trigger deals this large?
The patent cliff — when a pharma company's top-selling drug loses patent protection and generic competitors flood in, eroding revenue — is the single biggest driver of this M&A wave.
Case in point: Merck's cancer immunotherapy Keytruda generated $31.7 billion in sales last year, nearly half the company's total revenue. Its patent expires in 2028.
In plain terms = the most profitable product in the portfolio is about to become a commodity anyone can copy. Without a replacement, revenue falls off a cliff.
Goldman Sachs Americas M&A co-head Ben Wallace noted that strong balance sheets give CEOs the firepower to act, and investors are rewarding them for deploying it toward next-decade growth.
Who is spending the most — and on what?
Eli Lilly, valued at roughly $1.1 trillion and flush with cash from its obesity drugs, has been the most aggressive buyer: up to $7 billion for cancer biotech Kelonia Therapeutics, up to $7.8 billion for sleep-disorder developer Centessa, and up to $3.8 billion for psychedelic-drug firm AtaiBeckley.
GSK paid $10.6 billion for oncology biotech Nuvalent, whose two drugs could win FDA approval later this year.
AbbVie spent $10.9 billion on Apogee Therapeutics — whose atopic-dermatitis drug is in Phase III trials. AbbVie's stock rose nearly 10% in the week after the announcement.
This reflects the market's stance on proactive pipeline-building: it is not punishing spending — it is rewarding action.
How is the competitive landscape changing?
Biotech M&A is no longer a big-pharma-only game. Mid-cap players such as France's Servier and Denmark's Ipsen have each closed two deals this year, intensifying the fight for quality assets.
Stuart Cable, partner at Goodwin Procter, noted another shift: the number of private targets selling for multi-billion-dollar sums has risen sharply.
This means → more buyers, pricier targets, and a shrinking window for companies still sitting on the sidelines.
How has the policy environment helped?
Since taking office, the Trump administration's FTC has taken a more lenient stance on merger reviews.
Tariff threats have been temporarily lifted, and a pricing agreement between pharma and the administration has removed most profit-risk concerns.
Buoyed by the deal wave, the XBI biotech index hit a five-year high this month.
Can this wave last — and what is the key variable?
Eric Tokat, co-president of Centerview Partners, called the current environment "the most active market I have ever seen" — in the past, some companies always held back, "but today, everyone is moving."
Schroders fund manager Ailsa Craig noted that pharma companies want "assets they can use tomorrow," because the patent cliff is already at their doorstep.
In plain terms = when everyone is chasing the same pool of assets, acquisition premiums get bid up. Whether those premiums can be justified by future drug sales is the key variable for this wave's sustainability.
Content is for reference only, not financial advice.